Clinical Trials Logo

Retinal Vein Occlusion clinical trials

View clinical trials related to Retinal Vein Occlusion.

Filter by:

NCT ID: NCT03918590 Enrolling by invitation - Clinical trials for Diabetic Macular Edema

Post Intravitreal Injection Topical NSAID vs. Patching

Start date: December 3, 2018
Phase: Phase 4
Study type: Interventional

A prospective randomized trial, to evaluate post-injection comfort measures comparing topical NSAID (nepafenac 0.3% suspension) and patching.

NCT ID: NCT03908307 Completed - Macular Edema Clinical Trials

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Start date: July 25, 2019
Phase: Phase 4
Study type: Interventional

This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.

NCT ID: NCT03892434 Recruiting - Clinical trials for Branch Retinal Vein Occlusion With Macular Edema

Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO

Start date: March 18, 2019
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of sequential therapy with intravitreal dexamethasone implant followed by bevacizumab compared with bevacizumab monotherapy for macular edema (ME) secondary to retinal vein occlusion (RVO).

NCT ID: NCT03810313 Terminated - Clinical trials for Central Retinal Vein Occlusion

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

RAVEN
Start date: July 3, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

NCT ID: NCT03802630 Terminated - Clinical trials for Branch Retinal Vein Occlusion

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

RAPTOR
Start date: July 2, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

NCT ID: NCT03790852 Terminated - Clinical trials for Diabetic Macular Edema

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Start date: December 26, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg

NCT ID: NCT03778502 Recruiting - Clinical trials for Cerebral Vein Thrombosis

DOAC in Unusual Site Venous Thrombosis

DUST
Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.

NCT ID: NCT03762226 Recruiting - Clinical trials for Diabetic Macular Edema

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

Start date: September 1, 2018
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate the influence and prognostic value of systemic factors (such as the cardiovascular and metabolic status) on the treatment response to anti-VEGF therapy in macular edema due to diabetes or retinal vein occlusion.

NCT ID: NCT03753893 Completed - Macular Edema Clinical Trials

Ocular Manifestations in Rheumatic Diseases

Start date: May 1, 2013
Phase:
Study type: Observational

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

NCT ID: NCT03739593 Completed - Macular Edema Clinical Trials

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Start date: March 13, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, and potentially lower the incidence of steroid-related side effects without compromising efficacy.